Table 1.

Demographic and clinical characteristics by induction therapy

	LEN (−) N=133	LEN (+) N=186
Age at BMT [Median (IQR)]	59 (52, 65)	58 (52, 63)
Sex
Male	69 (52 %)	107 (58 %)
Female	64 (48 %)	79 (42 %)
Race
White	99 (74 %)	142 (76 %)
Black	32 (24 %)	39 (21 %)
Other	2 (2 %)	5 (3 %)
Durie–Salmon Stage at Diagnosis
I	14/77 (18 %)	16/104 (15.3 %)
II	13/77 (17 %)	15/104 (14.4 %)
III	50/77 (65 %)	73/104 (70.1 %)
Initial Priming Agent
G-CSF	104 (78 %)	139 (75 %)
G-CSF + GMCSF	0 (0 %)	4 (2 %)
Cyclophosphamide + G-CSF	14 (11 %)	14 (8 %)
Plerixafor + G-CSF	15 (11 %)	29 (16 %)
Induction cycles [median (IQR)]	5 (4, 7)	4 (4, 6)

G-CSF granulocyte-colony stimulating factor (filgrastim); GMCSF granulocyte-macrophage colony-stimulating factor (sargramostim); Median IQR median interquartile range represents the middle value between 25th and 75th percentile values